Recital 208, Commission Decision of 12/12/2023 declaring a concentration to be compatible with the co…

In forcesince 12 Dec 2023

Lastly, the majority of respondents to the market investigation considered that the

large portfolio of products of dairy enzymes and dairy cultures would not give the merged entity the ability to exclude rivals and it is not commercial practice to sell together the affected product bundles (lactase-protease, lactase-transglutaminase, coagulants-protease, coagulants-transglutaminase as well as any bundles across other relevant pairs).